Stoke Therapeutics, Zorevunersen, Dravet Syndrome, SCN1A, Antisense Oligonucleotide, ASO, RNA Medicine, TANGO, NaV1.1, Phase 3, EMPEROR, FDA, NDA,

BEDFORD, Mass. — October 5, 2026 Stoke Therapeutics, Inc. announced the completion of a successful meeting with the U.S....